A consortium to assist biomarkers reach their full potential

Biomarker commercialization (BiC)

Biomarkers are potential prognostic, diagnostic, and treatment indicators. Despite their increasing potential for precision medicine, their development into commercial products is very challenging. The purpose of a new Baltic Sea Region (BSR) consortium is to create tools for supporting and overcoming the challenges of biomarker commercialization.

The objectives of BIC consortium are to create:

  • a biomarker development tool for researchers
  • a screening and selection guide for TTOs
  • a framework for technology translation into clinical setting
  • new business model templates
  • a biomarker platform with access to the tools and technology presentations for match making

 

Funding Source

Funding Source

The project’s budget is EUR 2.55 million and is co-financed by the European Regional Development Fund through the Interreg Baltic Sea Region Programme with EUR 1.96 million.

Latest resources

Latest resources
BIC Best Practice Handbook
Latest resources
BIC Web Seminar #1

What users say about BIC and the BIC Guide...

Huram Konjen, CEO of Dianox

Huram Konjen, CEO of Dianox

“Overall, the BIC Commercialization Guide was tremendously helpful for us to organize the research and development of our technology. The process of bringing technology from idea to production stage – this is really where the BIC Commercialization Guide shines. External consultancies that offer services to help with this process can charge up to 5% equity ownership of a startup. Therefore, the tool is not only helpful but also has a high financial value."

Per Svenningsen, associate professor at University of Southern Denmark

“A tool like the BIC Commercialization Guide is much needed since the research and commercial fields are very different, i.e., publications create value in the research field, whereas market size creates value in the commercial area. The information provided in the BIC Commercialization Guide can help bridge the gap.”

Tomasz K Wojdacz and Lise Lotte Hansen from MethylDetect

“The division of each part of the tool into biomarker development, commercial evaluation and regulatory issues, provides a clear overview of requirements for each phase. This saves time by providing a highly useful guide through the commercialization procedure. The description of each step to be taken in the different categories are clear, well-described in short terms, and follows a logic and strict path.”

Anna-Riina Koskenniemi, LM, Doctoral Student, University of Turku

Anna-Riina Koskenniemi, LM, Doctoral Student, University of Turku

"This tool gives a lot of structure and validation to research. One does a lot of things in lab but doesn’t really understand the reasons and structure, until sees a tool like this! Many items per se were familiar to me, but it was good to really “see” them written down somewhere."

Dr. Sami Ventelä, researcher, PhD, MD, University of Turku / Turku Bioscience Centre

Dr. Sami Ventelä, researcher, PhD, MD, University of Turku / Turku Bioscience Centre

"It is good to remind researchers about the clinical and business aspects, especially the basic and non-clinician researchers. The focus is lost so easily when you have an interesting molecule and not much attention is given to commercial or practical aspects at that point. This tool facilitates more rational focus and development without wasting several months of lab work to something irrelevant."

Dr. Kamlesh Gidwani, Docent, Adjunct Professor at University of Turku

Dr. Kamlesh Gidwani, Docent, Adjunct Professor at University of Turku

"Very, very useful for any scientist or researcher working in biomarker discovery or development. There are lots of things we are going to include in our future processes and projects."

Janne O. Koskinen, Ph.D. R&D Director & Marketing Director, ArcDia International Oy Ltd

Janne O. Koskinen, Ph.D. R&D Director & Marketing Director, ArcDia International Oy Ltd

”The BIC tool is beneficial for all start ups and researchers aiming to take their results into clinical diagnostic use. The tool helps to grasp the regulatory requirements and academia to better understand the industry point of view.”

Allan Stensballe, Associate Professor Aalborg University

“Even with the abundance of new biomarkers being identified all the time not many make it past publication. Some of this may be due to lack of guidance and information about going from identifying a new potential biomarker to all the regulatory and commercial aspects that is also vital in biomarker commercialization. In this aspect, I believe the BIC Commercialization Guide fulfils a needed role that will help and ease the way for researchers considering commercializing biomarker research results.”

Aase Handberg, Clinical Professor at Aalborg University Hospital

"The structure around biomarker validation is very helpful, in particular for (clinical) researchers outside the diagnostic area or basic researchers with no or low clinical interface. The structure is also good as a common platform for communication between TTOs and researchers."

Close
What are you looking for?